Ask about this productRelated genes to: Pde4d antibody
- Gene:
- PDE4D NIH gene
- Name:
- phosphodiesterase 4D
- Previous symbol:
- DPDE3
- Synonyms:
- -
- Chromosome:
- 5q11.2-q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-08
- Date modifiied:
- 2018-07-11
Related products to: Pde4d antibody
Related articles to: Pde4d antibody
- A series of symmetric and asymmetric diarylpentanoids based on -isopropyl-4-piperidone were rationally designed and synthesized through a Claisen-Schmidt condensation reaction. This was done to investigate their potential as anticancer and anti-inflammatory agents. The synthesized compounds were evaluated for cytotoxic activity against the MCF-7 breast cancer cell line, as well as for nitric oxide inhibitory activity in LPS-stimulated RAW264.7 macrophages. Structure-activity relationship analysis revealed that the presence of electron-donating substituents and asymmetric aryl substitutions significantly enhanced biological activity. Among the synthesized derivatives, compound KB2d exhibited the strongest anticancer activity, with an IC value of 1.54 µM, while compound KB2c demonstrated promising anti-inflammatory activity, with an IC value of 2.51 µM. To understand the molecular basis of these activities, molecular docking simulations and 200 ns molecular dynamics were conducted on aromatase and PDE4D protein targets. The leading compound, KB2d, showed stable binding behavior, low ligand RMSD oscillations, and favorable binding free energy (Δ_bind ≈ -33 kcal mol) as calculated using the MM-PBSA method. These findings suggest that asymmetric -isopropyl-4-piperidone diarylpentanoids represent promising structural frameworks for the further development of anticancer and anti-inflammatory agents. - Source: PubMed
Publication date: 2026/05/01
Tran Huy-KhoaMai Truc-VyLe Van-DungMinh-An Tran-NguyenMai Dinh-TriTran Quoc-TuanQuyen Vu ThiNguyen Thanh-DanhDang Chi-Hien - Alzheimer's disease (AD) is characterized by amyloid-β deposition, neuroinflammation, and mitochondrial dysfunction. Phosphodiesterase 4 (PDE4), a key regulator of cyclic nucleotides in neurons, represents a promising therapeutic target for AD. In this study, we performed a PDE4 inhibition-guided screen of an in-house marine natural product library derived from marine fungi, leading to the identification of a sesterterpenoid variecolactone (VLT) as a potent PDE4 inhibitor. VLT exhibited selective PDE4D inhibition (IC = 2.302 μM) with minimal activity against other PDE subtypes. Further mechanical investigation revealed that VLT treatment elevated cAMP and p-CREB levels, reduced amyloid-β (Aβ) accumulation, promoted synaptic function, and ameliorated mitochondrial fragmentation, along with mtDNA homeostasis in the AD cell model. Moreover, under conditions of mtDNA depletion or Drp1 overexpression, VLT exerted neuroprotective effects and maintained mtDNA homeostasis via the cAMP-PKA-CREB signaling pathway. These results demonstrate that PDE4 inhibition by VLT represents a promising therapeutic strategy for AD and related neurodegenerative disorders. - Source: PubMed
Publication date: 2026/04/12
Fu TingtingShi YujiaYang ZhonglinZhou JuanHuang LingFu YingXiong Wandi - Tongue squamous cell carcinoma (TSCC) is clinically heterogeneous, and patients with a similar TNM stage can experience markedly different outcomes. We systematically reviewed omics-driven studies to identify prognostic TSCC biomarkers. Although fundamentally prognostic, we discussed their theoretical translational relevance regarding future clinical decisions-such as treatment stratification or surveillance intensity-while strictly framing them as preliminary, hypothesis-generating targets. PubMed, Scopus, Web of Science, and Cochrane were searched for original human studies published between 2014 and 2024 using high-throughput genomic or transcriptomic profiling. Study selection followed referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), data were extracted with a structured workbook, and risk of bias was assessed using QUIPS and PROBAST, with reporting completeness appraised using REMARK. Seventeen studies were included, identifying 85 distinct biomarkers. Across biomarkers supported by multivariable overall survival analyses, higher-risk associations were reported for , , , , and , whereas lower-risk associations were reported for , , , , and . Recurrent biological themes included IL-17 signaling, ECM-receptor interaction, and focal adhesion. was the only biomarker reported in more than one included study, supporting its prioritization for validation. Although the evidence remains heterogeneous and largely hypothesis-generating, these markers may support the future validation of response-oriented therapeutic stratification in TSCC. - Source: PubMed
Publication date: 2026/04/10
Astreidis IoannisKostidis IliasMalousi AndigoniParaskevopoulos KonstantinosAndreadis DimitriosVahtsevanos KonstantinosVizirianakis Ioannis - Canine oral cancers are difficult to manage due to complex biology and a lack of non-invasive biomarkers. Proteomic approaches, particularly gel-based liquid chromatography-tandem mass spectrometry (GeLC-MS/MS), have been used on tissue and saliva, but serum remains obscure despite its clinical accessibility and ability to reflect systemic disease. - Source: PubMed
Ploypetch SekkarinRoytrakul SittirukJaresitthikunchai JanthimaPhaonakrop NarumonSuriyaphol Gunnaporn - Ischemic stroke is a leading cause of neurological disability and death worldwide, and effective therapeutic agents targeting cerebral ischemia/reperfusion (I/R) injury remain urgently needed. α-Mangostin, a xanthone derivative isolated from mangosteen fruit, possesses neuroprotective activity. This study aimed to explore the neuroprotective effect of α-mangostin on oxygen-glucose deprivation and reperfusion (OGD/R)-stimulated human brain microvascular endothelial cells (hBMECs). Cell viability, apoptosis, and reactive oxygen species (ROS) content were evaluated by CCK-8 assay, flow cytometry, and ROS assay kit, respectively. Expression of phosphodiesterase 4D (PDE4D) was detected by qRT-PCR and western blot analysis. α-Mangostin targets were retrieved from SwissTargetPrediction and SEA databases and ischemic stroke-related targets were obtained from DisGeNet and GeneCards databases. A Venn diagram was used to identify overlapping targets. Targets of PDE4D in ischemic stroke were predicted using CTD database and subjected to KEGG pathway analysis. The changes in the mitogen-activated protein kinase (MAPK) pathway were examined by western blot analysis. Results showed that α-mangostin alleviated OGD/R-induced viability reduction and apoptosis in hBMECs. Moreover, α-mangostin abolished OGD/R-triggered inflammatory response and ROS generation in hBMECs. PDE4D was identified as the only intersecting target of α-mangostin against ischemic stroke. α-Mangostin inhibited PDE4D expression and PDE4D overexpression reversed the effects of α-mangostin on OGD/R-induced injury in hBMECs. KEGG analysis showed that targets of PDE4D were enriched in MAPK pathway. α-Mangostin inactivated the MAPK pathway by downregulating PDE4D expression. In conclusion, α-mangostin attenuates OGD/R-induced injury in hBMECs through inhibiting the MAPK pathway by downregulating PDE4D expression. These findings provide an experimental basis for further research on α‑mangostin in cerebral ischemia/reperfusion injury. - Source: PubMed
Publication date: 2026/04/23
Cao HongleiNiu YoushengLiu FeijiaoCao MiaoyuZhang Tao